World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
28605
World Ranking
12234
National Ranking
383

Christian Recher publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christian Recher sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 964 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christian Recher D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christian Recher sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christian Recher is affiliated with the Federal University of Toulouse Midi-Pyrénées in France. Their research primarily focuses on medicine, with significant contributions in biochemistry, genetics, and molecular biology. Within these fields, they specialize notably in hematology and molecular biology, with further engagement in genetics, oncology, and public health, environmental, and occupational health.

The scientist's work addresses various topics, including:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Acute Lymphoblastic Leukemia Research
  • Protein Degradation and Inhibitors
  • Multiple Myeloma Research and Treatments

Christian Recher has published extensively in several key scientific venues. The most frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Journal of Clinical Oncology
  • Leukemia

Their recent research papers cover a range of subjects mainly related to acute myeloid leukemia and related treatments. Noteworthy papers include:

  • "Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia," 2022, New England Journal of Medicine
  • "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia," 2020, Blood
  • "Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia," 2022, New England Journal of Medicine
  • "Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)," 2021, Journal of Clinical Oncology
  • "Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine," 2021, Journal of Clinical Oncology

Collaboration plays a notable role in their research activities. Frequent coauthors include:

  • Arnaud Pigneux
  • Sarah Bertoli
  • Éric Delabesse
  • Pierre-Yves Dumas
  • Pau Montesinos

Christian Recher's work contributes to understanding and improving therapies related to hematological malignancies, especially focusing on molecular and clinical aspects within acute and chronic myeloid leukemias, among other areas.

Best Publications

  • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    Hervé Dombret;John F. Seymour;Aleksandra Butrym;Agnieszka Wierzbowska

  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

    Alexander E. Perl;Giovanni Martinelli;Jorge E. Cortes;Andreas Neubauer

  • Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials

    Robert Kerrin Hills;Sylvie Castaigne;Frederick R. Appelbaum;Jacques Delaunay

  • Chemotherapy Resistant Human Acute Myeloid Leukemia Cells are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

    Thomas Farge;Thomas Farge;Estelle saland;Estelle saland;Fabienne de Toni;Fabienne de Toni;Nesrine Aroua;Nesrine Aroua

  • High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

    Arnaud Jaccard;Philippe Moreau;Véronique Leblond;Xavier Leleu

  • Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

    Thomas Prébet;Steven D. Gore;Benjamin Esterni;Claude Gardin

  • Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support.

    E Azoulay;C Alberti;C Bornstain;G Leleu

  • Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

    Jean-Emmanuel Sarry;Kathleen Murphy;Robin Perry;Patricia V. Sanchez

  • Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

    Raphael Itzykson;Sylvain Thépot;Bruno Quesnel;Francois Dreyfus

  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

    Céline Berthon;Emmanuel Raffoux;Xavier Thomas;Norbert Vey

  • Antileukemic activity of rapamycin in acute myeloid leukemia.

    Christian Récher;Odile Beyne-Rauzy;Cécile Demur;Gaëtan Chicanne

  • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

    Eric Jourdan;Nicolas Boissel;Sylvie Chevret;Eric Delabesse

  • Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

    Ruxanda Moschoi;Ruxanda Moschoi;Véronique Imbert;Véronique Imbert;Marielle Nebout;Marielle Nebout;Johanna Chiche;Johanna Chiche

  • Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.

    Nathalie Jacque;Anne Marie Ronchetti;Clément Larrue;Clément Larrue;Godelieve Meunier

  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

    Lionel Adès;Lionel Adès;Agnes Guerci;Emmanuel Raffoux;Miguel Sanz

  • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.

    Christian Récher;Bertrand Coiffier;Corinne Haioun;Thierry Jo Molina

  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

    Geoffrey L. Uy;Ibrahim Aldoss;Matthew C. Foster;Peter H. Sayre

  • Expression and prognostic significance of survivin in de novo acute myeloid leukaemia

    Colette Adida;Christian Recher;Emmanuel Raffoux;Marie‐Thérèse Daniel

  • Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab

    P. Feugier;J. M. Virion;H. Tilly;C. Haioun

  • MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

    Christiane Copie-Bergman;Christiane Copie-Bergman;Peggy Cuillière-Dartigues;Maryse Baia;Josette Briere

Frequent Co-Authors

Eric Delabesse
Eric Delabesse Cancer Research Center of Toulouse
Hervé Dombret
Hervé Dombret Université Paris Cité
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Stéphane de Botton
Stéphane de Botton Institut Gustave Roussy
Claude Preudhomme
Claude Preudhomme University of Lille
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Sylvie Chevret
Sylvie Chevret Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine, exploring online degrees and alternative healthcare career pathways can open up more flexible and affordable options. Many prospective medical professionals choose related fields that offer strong job opportunities, specialized skills, and the potential for career advancement.

One popular option is pursuing the cheapest master's in healthcare administration, ideal for those aiming for leadership roles in hospitals and clinics. For nurses wanting to reach the highest clinical positions, the most affordable dnp programs provide a cost-effective path to a Doctor of Nursing Practice degree.

Pharmacy is another in-demand field, and flexible learning is available through online pharmacy programs that deliver advanced training without relocating. Those interested in healthcare data or informatics may benefit from a bachelor of health information management online to prepare for roles in medical records, compliance, and technology.

By considering these accredited online programs, you can diversify your options and build a rewarding career in the expanding healthcare sector.

Best Scientists Citing Christian Recher

Trending Scientists

Recently Published Articles